Compare Abeona Therapeutics Inc (ABEO) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Quantumscape Corp — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Quantumscape Corp trades at $6.35 (market cap $3.81B). The key difference: Quantumscape Corp is far larger — about 9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| ABEO | QS | |
|---|---|---|
Market Cap | $424.33M | $3.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $18.44 |
52-Week Low | $4.17 | $4.89 |
Enterprise Value | $279.23M | $3.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
QuantumScape (QS) trades at $6.075, up 9.86% in the last session, with a bullish technical signal overall despite mixed moving averages and oscillators. The company reported a net loss of $435.05 million in 2025, with negative ROE and ROA, and has no revenue as it develops solid-state battery technology. Recent news highlights partnerships with Volkswagen and Honda, but the stock fell 31% in July 2026 amid commercialization delays.
The outlook remains speculative, with potential upside tied to successful battery commercialization by 2029, but high execution risks and persistent losses warrant caution. Analyst sentiment is neutral to bearish, with 73% hold ratings, reflecting uncertainty over timelines and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
